India to Georgia Pharmaceutical Export

The pharmaceutical trade between India and Georgia has experienced significant growth over the past decade. In 2024, India exported pharmaceutical products valued at $24.75 million to Georgia, marking a substantial increase from previous years. This upward trajectory reflects the strengthening of bilateral trade relations and India's expanding presence in the Georgian pharmaceutical market.

Key milestones in this evolution include the establishment of direct shipping routes and the participation of Indian pharmaceutical companies in Georgian trade fairs, which have facilitated market penetration. Additionally, the recognition of India's pharmaceutical manufacturing standards by Georgian regulatory authorities has played a pivotal role in enhancing trade volumes.

India holds a significant share of Georgia's pharmaceutical imports, positioning itself as a primary supplier alongside other origins such as China and the European Union. The strategic importance of this relationship is underscored by India's ability to offer a diverse range of pharmaceutical formulations that cater to Georgia's healthcare needs. The competitive pricing and adherence to international quality standards further bolster India's position in the Georgian market.

Between 2024 and 2026, several developments have influenced the India-Georgia pharmaceutical trade. In January 2022, Georgia amended its Law on Medicines and Pharmaceutical Activities to require a certificate confirming that imported pharmaceutical products are manufactured in line with Good Manufacturing Practice (GMP) standards. (rustavi2.ge) This regulatory change has prompted Indian exporters to ensure compliance with GMP to maintain market access. Additionally, diplomatic engagements and trade agreements have been initiated to further enhance bilateral trade relations, with ongoing discussions aimed at reducing trade barriers and facilitating smoother market entry for Indian pharmaceutical products.

Indian pharmaceutical companies seeking to register products in Georgia must navigate a structured process. The Georgian regulatory authority, the Regulation Agency for Medical and Pharmaceutical Activities, mandates that all pharmaceutical products be registered before importation. For products already approved by stringent regulatory authorities such as the FDA or EMA, Georgia offers a "Recognition Regime," allowing for a streamlined registration process that typically takes 7 working days. This regime is designed to expedite market entry for products with established international approvals. (legal.ge)

For other products, the "National Regime" applies, which involves a more comprehensive evaluation and can extend over several months. Regardless of the regime, a valid GMP certificate from the manufacturing site is mandatory for registration. This requirement ensures that imported pharmaceutical products meet the quality standards expected in the Georgian market. (legal.ge)

Georgia's adherence to international standards necessitates that Indian manufacturing facilities comply with GMP and Good Distribution Practice (GDP) standards. Since 2022, compliance with these standards has been mandatory for manufacturers, importers, and distributors operating in Georgia. (legal.ge) The inspection process involves a thorough assessment of the manufacturing premises, equipment, and quality control measures to ensure adherence to GMP standards. Mutual recognition agreements between Georgia and countries with stringent regulatory frameworks, such as the EU and the USA, facilitate the acceptance of GMP certifications from these jurisdictions, streamlining the process for Indian exporters.

Importing pharmaceutical products into Georgia requires specific documentation to ensure compliance with regulatory standards. A certificate of pharmaceutical product (CPP) in the form recommended by the World Health Organization is essential. If such a certificate is unavailable, a document certifying that the pharmaceutical product has been manufactured according to GMP standards or a pharmaceutical product manufacturing license issued by an authorized body of the manufacturing country is acceptable. (wipo.int) Additionally, a standard packaging with standard labeling, or an electronic version, of the pharmaceutical product to be registered is required. In the case of registration of an imported pharmaceutical product, an authorized (attested) translation of a patient information leaflet into the Georgian language and an original patient information leaflet, under procedures established by the Ministry, must be provided. (wipo.int)

India's pharmaceutical exports to Georgia are predominantly composed of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products align with Georgia's healthcare needs, particularly in the management of chronic conditions such as diabetes and cardiovascular diseases. The dominance of these categories is attributed to the high prevalence of such diseases in Georgia and the efficacy of Indian formulations in addressing these health concerns.

The expiration of patents for several blockbuster drugs presents opportunities for Indian exporters to introduce generic versions into the Georgian market. Additionally, the growing demand for biosimilars in Georgia offers a promising avenue for Indian pharmaceutical companies, given their expertise in biosimilar development. Exploring new therapeutic areas, such as oncology and immunology, could further diversify India's export portfolio to Georgia.

Georgia's disease burden, characterized by a high incidence of chronic illnesses like diabetes and hypertension, drives the demand for pharmaceutical imports. The aging population further exacerbates this demand, as older individuals typically require more medical care and medications. Increased healthcare spending and government initiatives to improve healthcare infrastructure also contribute to the rising need for pharmaceutical products, creating a favorable environment for Indian exporters.

Georgia's tariff structure for pharmaceutical products is designed to facilitate the importation of essential medicines while protecting domestic industries. Most-favored-nation (MFN) tariff rates apply to pharmaceutical imports, with preferential rates and duty exemptions available under specific trade agreements. These policies aim to balance the interests of domestic producers and international suppliers, ensuring the availability of quality medicines at competitive prices.

Georgia has engaged in various trade agreements to enhance bilateral relations and promote economic cooperation. While there is no specific Free Trade Agreement (FTA) between India and Georgia, both countries have expressed interest in exploring such agreements to reduce trade barriers and facilitate smoother market access for pharmaceutical products. Ongoing negotiations focus on harmonizing regulatory standards and addressing tariff and non-tariff barriers to trade.

Georgia's intellectual property (IP) laws provide protection for pharmaceutical patents, data exclusivity, and compulsory licensing. These provisions impact the entry of Indian generics into the Georgian market, as patent protections may limit the ability to produce and sell generic versions of patented drugs. Understanding the nuances of Georgia's IP landscape is crucial for Indian exporters to navigate potential challenges and identify opportunities for market entry.

Major sea and air routes facilitate the transportation of pharmaceutical products from Indian ports to Georgia. Sea routes typically involve transit through the Suez Canal, with an estimated transit time of 20-25 days, depending on the port of departure in India. Air freight offers faster delivery, with transit times ranging from 5 to 7 days. However, geopolitical events, such as disruptions in the Red Sea, can impact these routes, necessitating alternative planning and potential delays.

In India, key export ports include Ahmedabad ICD (6.2%), Delhi Air Cargo Acc (INDEL4) (9.2%), and Nhava Sheva Sea (INNSA1) (8.7%). In Georgia, primary import ports are Poti (16.2%), Tbilisi (4.0%), and Tbilisi (51.3%). These ports are equipped to handle pharmaceutical shipments, ensuring efficient customs clearance and distribution within Georgia.

Temperature-controlled logistics are essential for maintaining the efficacy of pharmaceutical products during transit. Compliance with Good Distribution Practice (GDP) standards is mandatory for pharmaceutical distributors in Georgia to ensure the quality of medicines during transport and storage. (legal.ge) Indian exporters must adhere to these standards, implementing robust cold chain management systems and ensuring packaging meets international compliance requirements to maintain product integrity upon arrival.

Georgia's pharmaceutical market has been experiencing steady growth, with an increasing reliance on imported medicines to meet domestic demand. The market's expansion is driven by factors such as an aging population, rising healthcare awareness, and government initiatives to improve healthcare infrastructure. The share of generics in the market is substantial, presenting opportunities for Indian exporters to introduce cost-effective alternatives to branded drugs.

Georgia's government healthcare programs aim to provide accessible and affordable medical services to its population. Insurance coverage is expanding, with more individuals gaining access to health insurance plans that cover a range of pharmaceutical products. The drug procurement system is centralized, with the government negotiating prices and managing the distribution of essential medicines, ensuring equitable access across the country.

Indian pharmaceutical exporters have specific opportunities in Georgia, particularly in the supply of generic medications for chronic diseases, biosimil